IL6 and prostate carcinoma: SiMoA has been previously implemented in studies for monitoring recurrence of prostate cancer after radical prostatectomy16, as well as tumor necrosis factor-alpha (TNF-α) and interleukin 6 (IL-6) for monitoring therapeutic efficacy in Crohn’s disease17.